The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Investigating luspatercept utilization patterns in lower-risk MDS
María Díez Campelo, MD, PhD, University of Salamanca, Salamanca, Spain, discusses a study investigating luspatercept utilization patterns in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in various countries. Dr Díez Campelo highlights that most patients were transfusion-dependent at the start of treatment, and few individuals received a dose increase, potentially impacting efficacy results. The study highlights luspatercept’s effectiveness in achieving and maintaining transfusion independence and reducing transfusion requirements in a real-world setting, confirming its role as a safe and effective treatment for patients with LR-MDS. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria/Speaker: BMS, Novartis, Keros; Advisory Board: BMS, Novartis, Blueprint Medicines, GSK, Agios, Hemavan, Syros, Keros, Curis, Astex/Otsuka.
